Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

🤖 Plain-English Summary

BACKGROUND: Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. CONCLUSIONS: Dostarlimab plus carboplatin-paclitaxel significantly increased progression-free survival among patients with primary advanced or recurrent endometrial cancer, with a substantial benefit in the dMMR-MSI-H population.

🔑 Key Findings

• The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of endometrial cancer.
• METHODS: We conducted a phase 3, global, double-blind, randomized, placebo-controlled trial.
• Eligible patients with primary advanced stage III or IV or first recurrent endometrial cancer were randomly assigned in a 1:1 ratio to receive either dostarlimab (500 mg) or placebo, plus carboplatin (area under the concentration-time curve, 5 mg per milliliter per minute) and paclitaxel (175 mg per square meter of body-surface area), every 3 weeks (six cycles), followed by dostarlimab (1000 mg) or placebo every 6 weeks for up to 3 years.

🔗 Related Resources